Invion

Invion Earnings Growth

The Year-over-Year Earnings Growth of Invion (IVX.AX) as of Oct 12, 2026 is 36.05 %. In the previous year, Year-over-Year Earnings Growth was -56.50 % — a change of -163.79% (higher).

Earnings Growth

36.05 %

YoY

-163.79%

Last updated:

Year-over-Year Earnings Growth of Invion is 2026 36.05 % . Year-over-Year Earnings Growth of Invion was 2025 -56.50 % . It decreases by -163.79% higher compared to the previous year.

The Invion Earnings Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Growth
Date
Earnings Growth
Jan 1, 2019
-174.82 AUD
Jan 1, 2020
62.54 AUD
Jan 1, 2021
-55.46 AUD
Jan 1, 2022
-51.14 AUD
Jan 1, 2023
27.95 AUD
Jan 1, 2024
-248.51 AUD
Jan 1, 2025
-56.50 AUD
Jan 1, 2026
36.05 AUD
The Invion Earnings Growth history
YEAREarnings GrowthYoY
36.05 %-163.79%
-56.50 %-77.26%
-248.51 %-988.98%
27.95 %-154.66%
-51.14 %-7.79%
-55.46 %-188.69%
62.54 %-135.77%
-174.82 %-402.03%
57.88 %+14.52%
50.54 %-23.30%
65.90 %-173.67%
-89.44 %—
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Year-over-Year Earnings Growth of Invion is 36.05 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Earnings Growth Invion since 2006 – with annual values, charts, and detailed analysis.

Earnings growth measures the percentage change in net income compared to the previous year. It reflects the company's improving or declining profitability.

To evaluate Year-over-Year Earnings Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Earnings Growth.

Year-over-Year Earnings Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Earnings Growth's Invion historically and in real time.

Access this data via the Eulerpool API

Growth — Invion

All Key Metrics — Invion